In clinical trials, pDNA encoding VEGF and hepatocyte growth factor (HGF) genes have been explored in phase 2 and phase 1/2 trials, respectively, for ALS treatment. The gene discussed is HGF; the disease is amyotrophic lateral sclerosis.